New drug combo aims to shrink brain tumors in advanced melanoma
NCT ID NCT05026983
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing two oral drugs, binimetinib and encorafenib, in 35 adults with advanced melanoma that has spread to the brain. The drugs block enzymes that help cancer cells grow. The study aims to see if this combination can control the disease and improve survival, while monitoring side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
binimetinib and encorafenib
What this could lead to
If successful, this could offer a new treatment option for people with melanoma that has spread to the brain, potentially helping to control the disease.
What could go wrong
This is a small, early-phase trial with only 35 participants, so results may not apply to everyone. The drugs can cause side effects like nausea, fatigue, and vision problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact